RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma has renewed its contract with Medi-Cal, ensuring Talicia’s continued availability without prior authorization and at no copay to 15 million Californians. This agreement upholds Talicia’s status as an approved first-line treatment for H. pylori infection, in line with the latest ACG Clinical Guideline. Talicia, a fixed-dose oral capsule, boasts a high H. pylori eradication rate and is designed to combat antibiotic resistance, with U.S. market exclusivity extending to 2034.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
